



IFW 1614

| TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT<br>(Under 37 CFR 1.97(b) or 1.97(c))  |             |          |              |                | Docket No.<br>RLL-293US |  |
|---|-------------|----------|--------------|----------------|-------------------------|--|
| In Re Application Of: Mehta et al.  |             |          |              |                |                         |  |
|    |             |          |              |                |                         |  |
| Application No.   | Filing Date | Examiner | Customer No. | Group Art Unit | Confirmation No.        |  |
| 10/552,456  | 08/14/2006  | Unknown  | 26815        | 1614           | 2308                    |  |
| Title: SUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS   |             |          |              |                |                         |  |
| Address to:<br>Commissioner for Patents<br>P.O. Box 1450<br>Alexandria, VA 22313-1450   |             |          |              |                |                         |  |
| 37 CFR 1.97(b)  |             |          |              |                |                         |  |
| 1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. |             |          |              |                |                         |  |
| 37 CFR 1.97(c)  |             |          |              |                |                         |  |
| 2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:   |             |          |              |                |                         |  |
| <input type="checkbox"/> the statement specified in 37 CFR 1.97(e);   |             |          |              |                |                         |  |
| OR  |             |          |              |                |                         |  |
| <input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).   |             |          |              |                |                         |  |

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
RLL-293US

In Re Application of: Mehta et al.



| Application No. | Filing Date | Examiner | Customer No. | Group Art Unit | Confirmation No. |
|-----------------|-------------|----------|--------------|----------------|------------------|
| 10/552,456      | 08/14/2006  | Unknown  | 26815        | 1614           | 2308             |

Title: SUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912  
as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

\*This certificate may only be used if paying by deposit account.

William D Hane  
Signature

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

September 20, 2006

\_\_\_\_\_  
(Date)

Christine Kenedy-Renner  
Signature of Person Mailing Correspondence

Christine Kenedy-Renner

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

Dated: September 20, 2006

CC:

# INFORMATION DISCLOSURE CITATION


Docket No.: RLL-293US

Serial No.: 10/552,456

Applicants: MEHTA *et al.*

Filed: 10/7/2005

Group:



## U.S. PATENT DOCUMENTS

| EXAMINER<br>INITIAL |    | DOCUMENT NUMBER | DATE       | NAME                    | CLASS | SUBCLASS | FILING DATE<br>IF APPROPRIATE |
|---------------------|----|-----------------|------------|-------------------------|-------|----------|-------------------------------|
|                     | A1 | 3,176,019       | 3/30/1965  | Campbell <i>et al.</i>  | 260   | 293.4    |                               |
|                     | A2 | 5,281,601       | 1/25/1994  | Cross <i>et al.</i>     | 514   | 320      |                               |
|                     | A3 | 5,397,800       | 3/14/1995  | Alker <i>et al.</i>     | 514   | 413      |                               |
|                     | A4 | 5,559,269       | 9/24/1996  | Johansson <i>et al.</i> | 564   | 443      |                               |
|                     | A5 | 5,948,792       | 9/7/1999   | Tsuchiya <i>et al.</i>  | 514   | 317      |                               |
|                     | A6 | 6,130,232       | 10/10/2000 | Mase <i>et al.</i>      | 514   | 318      |                               |
|                     | A7 | 6,174,900       | 1/16/2001  | Okada <i>et al.</i>     | 514   | 317      |                               |
|                     |    |                 |            |                         |       |          |                               |


## FOREIGN PATENT DOCUMENTS

|  |     | DOCUMENT NUMBER | DATE       | COUNTRY | CLASS | SUBCLASS | TRANSLATION<br>YES   NO |  |
|--|-----|-----------------|------------|---------|-------|----------|-------------------------|--|
|  | B1  | EP 0 325 571    | 7/26/1989  | EPO     | C07C  | 215/54   |                         |  |
|  | B2  | EP 0 388 054    | 9/19/1990  | EPO     | C07D  | 207/08   |                         |  |
|  | B3  | EP 0 801 067    | 10/15/1997 | EPO     | C07D  | 453/02   |                         |  |
|  | B4  | EP 0 823 423    | 2/11/1998  | EPO     | C07D  | 211/46   |                         |  |
|  | B5  | GB 940,540      | 10/30/1963 | UK      | C07C  |          |                         |  |
|  | B6  | JP 135958/1994  | 5/17/1994  | Japan   | C07D  | 333/16   |                         |  |
|  | B7  | JP 92921/1994   | 4/5/1994   | Japan   | C07C  | 237/20   |                         |  |
|  | B8  | WO 91/09013     | 6/27/1991  | PCT     | C07D  | 207/08   |                         |  |
|  | B9  | WO 93/16018     | 8/19/1993  | PCT     | C05F  | 17/02    |                         |  |
|  | B10 | WO 93/16048     | 8/19/1993  | PCT     | C07D  | 211/26   |                         |  |
|  | B11 | WO 96/33973     | 10/31/1996 | PCT     | C07D  | 211/46   |                         |  |
|  | B12 | WO 97/45414     | 12/4/1997  | PCT     | C07D  | 211/58   |                         |  |
|  | B13 | WO 98/00016     | 1/8/1998   | PCT     | A01N  | 43/38    |                         |  |
|  | B14 | WO 98/00109     | 1/8/1998   | PCT     | A61K  | 9/08     |                         |  |

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


|  |                                 |                        |
|--|---------------------------------|------------------------|
| <b>INFORMATION DISCLOSURE CITATION</b><br> | Docket No.: RLL-293US           | Serial No.: 10/552,456 |
|  | Applicants: MEHTA <i>et al.</i> |                        |
|  | Filed: 10/7/2005                | Group:                 |

|     |             |           |     |      |        |  |  |
|-----|-------------|-----------|-----|------|--------|--|--|
| B15 | WO 98/00132 | 1/8/1998  | PCT | A61K | 31/40  |  |  |
| B16 | WO 98/00133 | 1/8/1998  | PCT | A61K | 31/40  |  |  |
| B17 | WO 98/05641 | 2/12/1998 | PCT | C07D | 211/46 |  |  |
| B18 | WO 98/29402 | 7/9/1998  | PCT | C07D | 311/20 |  |  |
|     |             |           |     |      |        |  |  |

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

|     |   |
|-----|---|
| C1  | Kubo et al., "Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor", <i>Nature</i> , <u>323</u> (2):411-416 (1986)  |
| C2  | Bonner et al., "Identification of a Family of Muscarinic Acetylcholine Receptor Genes", <i>Science</i> , <u>237</u> :527-531 (1987)   |
| C3  | Eglen et al., "Muscarinic receptor ligands and their theraputic potential", <i>Current Opinion in Chemical Biology</i> , <u>3</u> :426-432 (1999)   |
| C4  | Eglen et al., "Theraputic opportunities from muscarinic receptor research", <i>Trends in Pharmacological Sciences</i> , <u>22</u> (8):409-414 (2001)  |
| C5  | Felder et al., "Theraputic Opportunities for Muscarinic Receptors in the Central Nervous System", <i>Journal of Medicinal Chemistry</i> , <u>43</u> (23):4333-4353 (2000)   |
| C6  | Broadley and Kelly, "Muscarinic Receptor Agonists and Antagonists", <i>Molecules</i> , <u>6</u> :142-193 (2001)   |
| C7  | Birdsall et al., "Muscarinic receptors: it's a knockout", <i>Trends in Pharmacological Sciences</i> , <u>22</u> (5):215-219 (2001)  |
| C8  | de Groat and Yoshimura, "Pharmacology of the Lower Urinary Tract", <i>Annual Review of Pharmacology and Toxicology</i> , <u>41</u> :691-721 (2001)  |
| C9  | Steers, "The future direction of neuro-urology drug research", <i>Current Opinion in CPNS Investigational Drugs</i> , <u>2</u> (3):268-282  |
| C10 | Chapple, "Muscarinic receptor antagonists in the treatment of overactive bladder", <i>Urology</i> , <u>55</u> (Suppl. 5A):33-46 (2000)  |
| C11 | Steers, Barrot, Wein, "Voiding dysfunction: diagnosis classification and management", In: <i>Adult and Pediatric Urology</i> , ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996) |
| C12 | Sagara et al., "Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M3 Antagonist Discriminating against the Other Receptor Subtypes", <i>Journal of Medicinal Chemistry</i> , <u>45</u> :984-987 (2002)    |
| C13 | Braish et al., "Construction of the (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-6-Amino-3-azabicyclo[3.1.0]hexane Ring System", <i>Synlett</i> , 1100-1102 (1996)   |

|   |                 |
|---|-----------------|
| EXAMINER  | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                 |

|  |                                 |                        |
|--|---------------------------------|------------------------|
| <b>INFORMATION DISCLOSURE CITATION</b><br> | Docket No.: RLL-293US           | Serial No.: 10/552,456 |
|  | Applicants: MEHTA <i>et al.</i> |                        |
|  | Filed: 10/7/2005                | Group:                 |

|  |     |  |
|--|-----|--|
|  |     | Moriya et al., "Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland", <i>Life Sciences</i> , <u>64</u> (25):2351-2358 (1999)   |
|  | C15 | Cheng and Prusoff, "Relationship between the inhibition constant ( <i>K</i> <sub>1</sub> ) and the concentration of inhibitor which causes 50 per cent inhibition ( <i>I</i> <sub>50</sub> ) of an enzymatic reaction", <i>Biochemical Pharmacology</i> , <u>22</u> :3099-3108 (1973)                |
|  | C16 | Andersson et al, "Asymmetric Total Synthesis of (+)-Tolterodine, a New Muscarinic Receptor Antagonist, via Copper-Assisted Asymmetric Conjugate Addition of Aryl Gridngard Reagents to 3-Phenyl-prop-2-enoyl-oxazolidinones", <i>Journal of Organic Chemistry</i> , <u>63</u> (22): 8067-8070 (1998) |
|  |     |  |

|   |                 |
|---|-----------------|
| EXAMINER  | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                 |